Skip to main content

Inflammation and Cardiometabolic Disease

Call for Papers

Cardiovascular Diabetology is welcoming papers for the collection Inflammation and cardiometabolic diseases, guest edited by Enrique Fisman: Tel Aviv University, Israel.

The striking relationship between cardiovascular diseases and glucose metabolism imbalance has raised the likelihood that atherosclerosis and type 2 diabetes (T2DM) may share common antecedents. Inflammation is emerging as a plausible etiologic mechanism for both ailments. Both epidemiological and genetic studies indicate that increased pro-inflammatory biomarkers are associated with the development of insulin resistance, diabetes, and cardiovascular disease. Moreover, several constituents of the immune system present various degrees of inflammatory alterations in patients T2DM. Knowledge of the pathophysiological changes involved in the occurrence of T2DM and its related complications is critical for achieving a successful prevention, diagnosis and treatment. Genetic polymorphisms encoding production of inflammatory cytokines and increased level of inflammatory biomarkers are usually associated to chronic pathologic conditions in TDM2.The most apparent clinical changes are observed in the heart, the kidneys, the eyes, the adipose tissue, the liver, the pancreatic islets and the vasculature. In the "Inflammation and cardiometabolic diseases" collection of Cardiovascular Diabetology we will be happy to consider for publication original articles or reviews on diagnostic and therapeutic aspects related to this field, as well as on novel connected technologies. 

This Collection welcomes submission of Research Articles, Data Notes, Case Reports, Study Protocols, and Database Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Inflammation and cardiometabolic diseases" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

  1. Previous studies have reported that inflammatory responses can promote the onset of cardiovascular diseases; however, its association with cardiac conduction disorders remains unclear. The present community-ba...

    Authors: Lili Wu, Meimei Wu, Dandan Zhao, Shuohua Chen, Guodong Wang, Lina Xu, Yujing Wang, Lina An, Shouling Wu, Congliang Miao and Jiang Hong
    Citation: Cardiovascular Diabetology 2023 22:268
  2. Diabetes poses a significant threat to human health. There is a lack of large-scale cohort studies to explore the association between mortality risk and indicators beyond blood glucose monitoring in diabetic p...

    Authors: Fan Yang, Mingsi Wang, Yuzhu Chen, Jianjun Wu and Yilan Li
    Citation: Cardiovascular Diabetology 2023 22:265
  3. The global prevalence of metabolic syndrome and its association with increased morbidity and mortality has been rigorously studied. However, the true prevalence of “metabolic health”, i.e. individuals without ...

    Authors: Hadas Ben-Assayag, Rafael Y. Brzezinski, Shlomo Berliner, David Zeltser, Itzhak Shapira, Ori Rogowski, Sharon Toker, Roy Eldor and Shani Shenhar-Tsarfaty
    Citation: Cardiovascular Diabetology 2023 22:226
  4. High-sensitivity C-reaction protein (hsCRP), a biomarker of residual inflammatory risk, has been demonstrated with poor cardiovascular outcomes. We aimed to investigate the prognostic value of hsCRP in patient...

    Authors: Le Li, Shangyu Liu, Zhuxin Zhang, Likun Zhou, Zhenhao Zhang, Yulong Xiong, Zhao Hu and Yan Yao
    Citation: Cardiovascular Diabetology 2023 22:223
  5. The accumulation of advanced glycation end products (AGEs) is associated with cardiovascular events in patients with cardiovascular disease (CVD). However, the relationship between the AGEs measured by an AGEs...

    Authors: Tomoya Hirai, Kazuhiro Fujiyoshi, Satoru Yamada, Takuya Matsumoto, Junko Kikuchi, Kohki Ishida, Miwa Ishida, Kyo Shigeta and Taiki Tojo
    Citation: Cardiovascular Diabetology 2023 22:213
  6. While a low-carbohydrate diet (LCD) reduces HbA1c in patients with type 2 diabetes (T2D), the associated high intake of fat may adversely affect cardiovascular risk factors. To address this, we examined the ef...

    Authors: Eva M. Gram-Kampmann, Thomas B. Olesen, Camilla D. Hansen, Mie B. Hugger, Jane M. Jensen, Aase Handberg, Henning Beck-Nielsen, Aleksander Krag, Michael H. Olsen and Kurt Højlund
    Citation: Cardiovascular Diabetology 2023 22:212
  7. Both elevated inflammation and atherogenic dyslipidemia are prominent in young-onset diabetes and are increasingly identified as biologically intertwined processes that contribute to diabetogenesis. We aimed t...

    Authors: Yulong Lan, Dan Wu, Zhiwei Cai, Yuancheng Xu, Xiong Ding, Weiqiang Wu, Shaocong Lan, Lan Chen, Zheng Guo, Lois Balmer, Xingang Li, Manshu Song, Shouling Wu, Jingli Gao, Wei Wang and Youren Chen
    Citation: Cardiovascular Diabetology 2023 22:181
  8. Higher chemokine C-X-C motif ligand 5 (CXCL5) level was observed in type 2 diabetes mellitus (DM) patients; however, its role in diabetic vasculopathy was not clarified. This study aimed to explore the impacts...

    Authors: Ching Chen, Liang-Yu Lin, Jaw-Wen Chen and Ting-Ting Chang
    Citation: Cardiovascular Diabetology 2023 22:172

    The Correction to this article has been published in Cardiovascular Diabetology 2023 22:196

  9. SGTL2-inhibitors are a cornerstone in the treatment of heart failure, but data on patients with acute myocardial infarction (AMI) is limited. The EMMY trial was the first to show a significant reduction in NTp...

    Authors: Martin Benedikt, Harald Mangge, Faisal Aziz, Pero Curcic, Sabine Pailer, Markus Herrmann, Ewald Kolesnik, Norbert J. Tripolt, Peter N. Pferschy, Markus Wallner, Andreas Zirlik, Harald Sourij and Dirk von Lewinski
    Citation: Cardiovascular Diabetology 2023 22:166
  10. This study aimed to investigate the impact of lipoprotein(a) [Lp(a)] levels on the prognosis of Chinese patients with ST-segment elevation myocardial infarction (STEMI), and to explore if the impact may differ...

    Authors: Nan Li, Jinying Zhou, Runzhen Chen, Xiaoxiao Zhao, Jiannan Li, Peng Zhou, Chen Liu, Yi Chen, Ying Wang, Li Song, Shaodi Yan, Hanjun Zhao and Hongbing Yan
    Citation: Cardiovascular Diabetology 2023 22:151
  11. The atherogenic index of plasma (AIP) is an important alternative metabolic biomarker of atherosclerosis and cardiovascular diseases. Nevertheless, the correlation between the AIP and carotid atherosclerosis i...

    Authors: Qin Huang, Zeyu Liu, Minping Wei, Qing Huang, Jie Feng, Zunjing Liu and Jian Xia
    Citation: Cardiovascular Diabetology 2023 22:125

    The Correction to this article has been published in Cardiovascular Diabetology 2023 22:246

  12. Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation ...

    Authors: Meng-Meng Yu, Xin Zhao, Yin-Yin Chen, Xin-Wei Tao, Jun-Bo Ge, Hang Jin and Meng-Su Zeng
    Citation: Cardiovascular Diabetology 2023 22:121
  13. Randomized controlled trials confirm that risks of residual cholesterol and residual inflammation remains in patients with cardiovascular disease (CVD) even after lipid-lowering therapy. This study aims to inv...

    Authors: Ling Yang, Qing Yue, Fang Fang, Yinggen Zhang, Peipei Liu, Zihao Zhang, Guodong Wang, Shuohua Chen, Shouling Wu and Xiuhong Yang
    Citation: Cardiovascular Diabetology 2023 22:96
  14. Diabetes mellitus (DM) and atherosclerosis are multifactorial conditions and share a common inflammatory basis. Three-vessel disease (TVD) represents a major challenge for coronary intervention. Nonetheless, t...

    Authors: Lei Guo, Haichen Lv, Junjie Wang, Bo Zhang, Yifan Zhu, Xiaoyan Zhang, Hao Zhu, Xuchen Zhou and Yunlong Xia
    Citation: Cardiovascular Diabetology 2023 22:91
  15. Obesity is linked to cardiometabolic diseases, however non-obese individuals are also at risk for type 2 diabetes (T2D) and cardiovascular disease (CVD). White adipose tissue (WAT) is known to play a role in b...

    Authors: Narmadha Subramanian, Kaisa Hofwimmer, Beatriz Tavira, Lucas Massier, Daniel P Andersson, Peter Arner and Jurga Laurencikiene
    Citation: Cardiovascular Diabetology 2023 22:84

    The Correction to this article has been published in Cardiovascular Diabetology 2023 22:229

  16. Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surg...

    Authors: Alexander Kogan, Avishay Grupper, Avi Sabbag, Eilon Ram, Tamer Jamal, Eyal Nof, Enrique Z. Fisman, Shany Levin, Roy Beinart, Jonathan Frogel, Ehud Raanani and Leonid Sternik
    Citation: Cardiovascular Diabetology 2023 22:77

    The Correction to this article has been published in Cardiovascular Diabetology 2023 22:116

  17. Diabetes mellitus is one of the prime risk factors for cardiovascular complications and is linked with high morbidity and mortality. Diabetic cardiomyopathy (DCM) often manifests as reduced cardiac contractili...

    Authors: Santosh K Sanganalmath, Shubham Dubey, Sudhakar Veeranki, Keerthy Narisetty and Prasanna Krishnamurthy
    Citation: Cardiovascular Diabetology 2023 22:37